- Home
- PYN vs EQ Comparison
PYN vs EQ Comparison
Compare PYN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- EQ
- Stock Information
- Founded
- PYN 2002
- EQ 2017
- Country
- PYN United States
- EQ United States
- Employees
- PYN N/A
- EQ N/A
- Industry
- PYN Investment Managers
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- EQ Health Care
- Exchange
- PYN Nasdaq
- EQ Nasdaq
- Market Cap
- PYN 34.6M
- EQ 39.0M
- IPO Year
- PYN N/A
- EQ 2018
- Fundamental
- Price
- PYN $6.04
- EQ $0.71
- Analyst Decision
- PYN
- EQ Buy
- Analyst Count
- PYN 0
- EQ 2
- Target Price
- PYN N/A
- EQ $5.00
- AVG Volume (30 Days)
- PYN 19.9K
- EQ 311.1K
- Earning Date
- PYN 01-01-0001
- EQ 11-13-2024
- Dividend Yield
- PYN 5.07%
- EQ N/A
- EPS Growth
- PYN N/A
- EQ N/A
- EPS
- PYN N/A
- EQ N/A
- Revenue
- PYN N/A
- EQ $45,914,000.00
- Revenue This Year
- PYN N/A
- EQ N/A
- Revenue Next Year
- PYN N/A
- EQ N/A
- P/E Ratio
- PYN N/A
- EQ N/A
- Revenue Growth
- PYN N/A
- EQ 7.70
- 52 Week Low
- PYN $4.84
- EQ $0.48
- 52 Week High
- PYN $6.60
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- PYN 45.93
- EQ 39.09
- Support Level
- PYN $5.97
- EQ $0.68
- Resistance Level
- PYN $6.11
- EQ $0.89
- Average True Range (ATR)
- PYN 0.10
- EQ 0.11
- MACD
- PYN 0.01
- EQ -0.03
- Stochastic Oscillator
- PYN 33.43
- EQ 5.49
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.